Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Descrición completa

Detalles Bibliográficos

Principais autores:	Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2018-09-01
Series:	Cancer Medicine
Assuntos:	eribulin metastatic breast cancer real‐world survival triple negative
Acceso en liña:	https://doi.org/10.1002/cam4.1705
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!